NICE rejects Novartis migraine drug

Jan 10, 2019

Britain's National Institute for Health and Care Excellence (NICE) rejected Novartis’s migraine drug, Aimovig, concluding that the drug was not a cost-effective use of resources.

While NICE found that the drug demonstrated clinical effectiveness, the agency concluded there was not enough evidence to suggest it is more effective than Allergan's Botox. NICE also raised questions about long-term effectiveness.

The decision comes just months after the price watchdog declined to endorse Novartis' cell therapy, Kymriah, in adult lymphoma patients.

Read the Reuters coverage

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments